Latest news
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59 - MoomooMoomoo · Fri, 07 Aug 2026 18:41:53 GMTEdgewise Therapeutics Q2 Net Loss Widens to $57.3 Million - MoomooMoomoo · Thu, 06 Aug 2026 12:16:35 GMTEdgewise Therapeutics Gains as Investors Weigh Cash-rich Reset and Cardiovascular Pipeline Progress - MoomooMoomoo · Tue, 04 Aug 2026 21:26:08 GMT